Search Results

Gore REDUCE Trial Evaluates Cardioform Device for PFO Closure

September 19, 2017—Lars Søndergaard, MD, et al published the findings from the Gore REDUCE Trial in The New England Journal of Medicine (NEJM;2017;377:1033–1042).

TAVR Comparable to SAVR in Lower-Risk Patients at 2 Years in NOTION

May 19, 2015—The results of the Nordic Aortic Valve Intervention (NOTION) trial were presented by Lars Søndergaard, MD, in the opening Hot Line session of the EuroPCR 2015 meeting being held May 19–22 in Paris, France.

SURTAVI Compares Completely Percutaneous Approach to TAVR and PCI Versus SAVR and CABG for Intermediate-Risk Patients

September 10, 2019—Results from the randomized SURTAVI trial were published by Lars Søndergaard, MD, et al in Circulation.

One-Year Results From PORTICO I Presented for Abbott's Portico TAVR Device

September 28, 2018—Abbott Structural Heart announced 1-year results from the PORTICO I trial, a real-world, international, multicenter, 941-patient study of the company's Portico transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic stenosis.

CardiAQ Reports First Transapical Implantation of Its Second-Generation TMVI System

May 20, 2014—CardiAQ Valve Technologies, Inc. announced a successful initial procedure with the company’s second-generation transcatheter mitral valve implantation (TMVI) system in an 88-year-old woman experiencing severe mitral regurgitation (MR 4+) using the company’s newly added transapical delivery system.

FDA Approves the Gore Cardioform Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke

April 3, 2018—Gore & Associates announced that it has received approval from the US Food and Drug Administration (FDA) for an expanded indication of its Gore Cardioform septal occluder for the closure of patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in certain patients.

Abbott’s Navitor TAVI System Receives CE Mark

May 17, 2021—Abbott announced its Navitor transcatheter aortic valve implantation (TAVI) system has received CE Mark.